Saniona AB (STO:SANION), a biotechnology company within ion-channel research, announced on Thursday the selection by Boehringer Ingelheim of the first candidate for pre-clinical and clinical development under Saniona's and Boehringer Ingelheim's collaboration in schizophrenia.
As a result of this candidate selection by Boehringer Ingelheim, Saniona will now receive a research milestone of EUR4.0m.
Saniona had entered into a drug discovery and development collaboration with Boehringer Ingelheim in 2016. This collaboration focuses on research of new small molecule therapeutics that could be capable of restoring brain network activity in patients with schizophrenia.
Also, Saniona may receive up to EUR90m in milestone payments including an upfront payment of EUR5m, which was paid upon signing of the agreement. These milestone payments include up to EUR50m upon the achievement of certain research, development and regulatory milestones and up to EUR35m n in commercial milestone.
In addition, Saniona is entitled to tiered royalties on net sales of any potential products commercialised by Boehringer Ingelheim as a result of this collaboration. Following the above milestone payment of EUR4m, Saniona will have received a total of EUR9m under the collaboration.
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca